Shareholders back NLS Pharmaceutics (NASDAQ: NLSP) merger with Kadimastem

Rhea-AI Filing Summary

NLS Pharmaceutics Ltd. reported that its shareholders have approved a planned merger with Kadimastem and related proposals at an extraordinary general meeting. This information is conveyed through a press release titled “NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting,” which the company furnished as Exhibit 99.1 to this Form 6-K. The report is signed on behalf of NLS Pharmaceutics by Chief Executive Officer Alexander Zwyer.

Positive

• Shareholders approved the merger with Kadimastem and related proposals at an extraordinary general meeting, clearing a major internal milestone for completing the transaction.

Negative

• None.

Insights

M&A and equity analyst

Shareholder approval moves the NLS–Kadimastem merger past a key corporate hurdle.

The filing states that NLS Pharmaceutics shareholders approved a merger with Kadimastem, along with related proposals, at an extraordinary general meeting. Shareholder approval is typically one of the most significant internal steps in a merger process, because it confirms that owners of the company have formally endorsed the transaction structure presented to them.

The report does not detail the financial terms, exchange ratios, or closing timeline, but it confirms that the corporate consent needed from NLS shareholders has been obtained. Future disclosures in company filings may provide additional information on regulatory approvals, closing conditions, or integration steps that follow this approval.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of September 2025 (Report No. 4)

Commission file number: 001-39957

NLS PHARMACEUTICS LTD.

(Translation of registrant’s name into English)

The Circle 6

8058 Zurich, Switzerland

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

On September 30, 2025, NLS Pharmaceutics Ltd. issued a press release titled: “NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting.” A copy of this press release is furnished herewith as Exhibit 99.1.

1

EXHIBIT INDEX

Exhibit Number		Description of Document
99.1		Press release titled: “NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting.”

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NLS Pharmaceutics Ltd.
Date: September 30, 2025	By:	/s/ Alexander Zwyer
		Name:	Alexander Zwyer
		Title:	Chief Executive Officer

3

FAQ

What did NLS Pharmaceutics (NLSP) disclose in this Form 6-K?

NLS Pharmaceutics disclosed that its shareholders approved a merger with Kadimastem and related proposals at an extraordinary general meeting, as described in a press release furnished as Exhibit 99.1.

What merger did NLS Pharmaceutics (NLSP) shareholders approve?

Shareholders of NLS Pharmaceutics approved a merger with Kadimastem, as indicated by the press release titled “NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting.”

How was the shareholder approval of the Kadimastem merger communicated?

The approval was communicated through a press release dated in connection with September 30, 2025, which NLS Pharmaceutics furnished as Exhibit 99.1 to this Form 6-K.

What is Exhibit 99.1 in the NLS Pharmaceutics (NLSP) Form 6-K?

Exhibit 99.1 is the press release titled “NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting.”

Who signed the NLS Pharmaceutics (NLSP) Form 6-K related to the Kadimastem merger approval?

The Form 6-K was signed on behalf of NLS Pharmaceutics Ltd. by Alexander Zwyer, who is identified as the company’s Chief Executive Officer.